Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.75 (market cap $7.97B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PDBC | SYRE | |
|---|---|---|
Market Cap | $7.97B | $7.35B |
Volume | 3,246,731 | 1,624,631 |
52-Week High | $20.10 | $108.92 |
52-Week Low | $13.19 | $22.18 |
Typical Hold Time | 56 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $19.98, up 0.6% on the day, with a strong bullish technical signal from moving averages. The ETF has delivered robust performance, rising 45.66% year-to-date through Q3 2026, driven by gains in energy and agricultural commodities amid geopolitical tensions. Institutional interest is growing, with several advisors increasing positions recently, though short interest also surged significantly in September.
The outlook for PDBC remains positive given ongoing commodity strength and defensive investor shifts, but risks include heightened short interest and geopolitical volatility that could pressure returns. Investors should weigh the ETF's momentum against potential pullbacks from overbought conditions and external shocks.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
